NCT01256151

Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet

Open-label, Randomized, Single-Dose, 2 Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Immediate Release Tablet

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To assess if the sublingual tablet will have similar pharmacokinetics as the conventional tablet of alprazolam.

Conditions

• Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Alprazolam tablet	1 mg single dose of alprazolam conventional tablet
DRUG	Alprazolam sublingual	1 mg single dose of alprazolam sublingual tablet

Timeline

• Start date: 2011-01-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2010-12-08
• Last updated: 2021-01-28

Locations

1 site across 1 country: United States